Research Blogs

March 05, 2024

From Leukemia to ALK+ NSCLC: Finding a New Way to Overcome Drug Resistance

Read Time: 5 minutes Approximately 4% of patients diagnosed with non-small cell lung cancer (NSCLC) will have their tumors test positive for an ALK biomarker. This means the ALK

READ MORE about From Leukemia to ALK+ NSCLC: Finding a New Way to Overcome Drug Resistance›
February 20, 2024

Using T cells to Tackle Drug Resistance in EGFR+ Lung Cancer

Approximately 10%-15% of patients with non-small cell lung cancer have tumors with mutations in the EGFR (epidermal growth factor receptor) gene. EGFR mutations are known to drive

READ MORE about Using T cells to Tackle Drug Resistance in EGFR+ Lung Cancer›
January 23, 2024

Top 5 Most Popular Blogs from 2023

LUNGevity blogs share personal stories, research updates, scientific meeting takeaways, policy news, and much more. Joining our Email List will help you stay updated on these

READ MORE about Top 5 Most Popular Blogs from 2023›
December 12, 2023

Creating a Best Practices Roadmap for Lung Cancer Screening Implementation

Finding lung cancer in its early stages significantly increases the chance of successfully treating and even curing the disease. Low-dose CT is the current approved approach to

READ MORE about Creating a Best Practices Roadmap for Lung Cancer Screening Implementation›
December 05, 2023

Building a Computational Model to Optimize Patient Treatment

Approximately 20%-35% of patients newly diagnosed with non-small cell lung cancer (NSCLC) will have locally advanced disease, sometimes referred to as stage III NSCLC. The

READ MORE about Building a Computational Model to Optimize Patient Treatment›
November 14, 2023

Treatment & Research Takeaways: ESMO 2023 Meeting

The European Society for Medical Oncology (ESMO) recently held its annual conference from October 20 – 24, 2023 in Madrid, Spain. ESMO represents one of the largest gatherings of

READ MORE about Treatment & Research Takeaways: ESMO 2023 Meeting›
November 07, 2023

Innovative Therapeutic Vaccine for ALK+ NSCLC Heads to Phase 1 Clinical Trial

Different types of lung cancer are known to be caused, or driven, by alterations in genes such as EGFR or ALK. One such alteration, the fusion of the ALK gene with another gene

READ MORE about Innovative Therapeutic Vaccine for ALK+ NSCLC Heads to Phase 1 Clinical Trial›
October 16, 2023

The Latest Lung Cancer Science: Highlights of WCLC 2023

I had the privilege of attending the 2023 World Conference on Lung Cancer (WCLC) in Singapore with my colleague Dr. Bellinda King-Kallimanis. WCLC, the world's largest meeting

READ MORE about The Latest Lung Cancer Science: Highlights of WCLC 2023›
August 15, 2023

The Path to Progress: One Researcher’s Journey to a Blood Test for Lung Cancer

Currently, lung cancer screening using low-density computed tomography (LDCT) scans is available as a tool to screen for lung cancer in individuals at high risk of developing the

READ MORE about The Path to Progress: One Researcher’s Journey to a Blood Test for Lung Cancer›
June 22, 2023

2023 ASCO: Highlights of Lung Cancer Research

Recently, members of LUNGevity Foundation joined thousands of attendees from the US and around the world, including oncologists, scientists, biotech and pharmaceutical

READ MORE about 2023 ASCO: Highlights of Lung Cancer Research›
June 06, 2023

LUNGevity Research Digs Deep Into Remote Patient Monitoring in Rural Communities

Since 2016, the medical community has seen strong data showing that remote patient monitoring (RPM), which gives people living with cancer simple ways to report treatment side

READ MORE about LUNGevity Research Digs Deep Into Remote Patient Monitoring in Rural Communities›
June 02, 2023

LUNGevity Research Delves into Patient Experiences with Biomarker Testing

Since 2020, LUNGevity has been engaged in research to understand the experiences of lung cancer patients, particularly those receiving care at community hospitals and those from

READ MORE about LUNGevity Research Delves into Patient Experiences with Biomarker Testing›